# Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

> **NCT00179712** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 60 (—)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** CC-5013
- **DRUG:** topotecan

## Key facts

- **NCT ID:** NCT00179712
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 60 (—)
- **Last updated:** 2016-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179712, "Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00179712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*